SCHEMBL281573

SCHEMBL281573

OCc1ccc(Cl)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16344564 0.80
SCHEMBL183551 0.80
SCHEMBL509883 0.78 TDP1 (0.38)
SCHEMBL30688993 0.77 ALDH1A1 (0.54)
SCHEMBL29111193 0.77 ALDH1A1 (0.54)
SCHEMBL282247 0.76
SCHEMBL20163169 0.74
SCHEMBL24304833 0.72 ALDH1A1 (0.55)
SCHEMBL901053 0.72 ALDH1A1 (0.50)
SCHEMBL6827419 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025060978-A1 TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF 科辉智药(深圳)新药研究中心有限公司 2025-03-27 WO disclosed
CN-119661547-A Tricyclic pyridine compounds as SARM1 enzyme activity inhibitors and application thereof 科辉智药(深圳)新药研究中心有限公司 2025-03-21 CN disclosed
EP-3241834-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2017-11-08 EP disclosed
US-9365540-B2 Benzimidazole derivatives as MCH receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
EP-2802571-A1 BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2014-11-19 EP disclosed
EP-2428515-B9 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2014-09-17 EP disclosed
EP-2752417-A1 Spiro-oxindole compounds and their uses as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2014-07-09 EP disclosed
EP-2428515-B1 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2014-05-07 EP disclosed
CN-103271906-A Use of spiro-oxindole compounds as therapeutic agents XENON PHARMACEUTICALS INC 2013-09-04 CN disclosed
WO-2013105676-A1 BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-18 WO disclosed
US-20100125072-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-05-20 US disclosed
WO-2010053998-A1 SPIRO-CONDENSED INDOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS, INC. (CA) 2010-05-14 WO disclosed
US-7700641-B2 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2010-04-20 US disclosed
CN-101631546-A Use of spiro-indolone compounds as therapeutic agents XENON PHARMACEUTICALS INC 2010-01-20 CN disclosed
EP-2073806-A2 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-07-01 EP disclosed
WO-2008060789-A2 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-05-22 WO disclosed
CN-101184761-A Spiro-indolone compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-05-21 CN disclosed
EP-1888595-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-02-20 EP disclosed
US-20060252812-A1 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2006-11-09 US disclosed
WO-2006110917-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-19 WO disclosed